Hepatocellular Carcinoma – Long-Term Treatable Disease

Česká verze

Authors: J. Fínek
Authors place of work: Onkologické a radioterapeutické oddělení, FN a LF UK v Plzni
Published in the journal: Klin Onkol 2012; 25(4): 287-289
Category: Kazuistiky

Summary

Case report –⁠ 30 months surviving patient with unresectable hepatocellular carcinoma treated with sorafenib.

Key words:
hepatocellular carcinoma –⁠ antineoplastic drugs –⁠ molecular targeted therapy

The author declares he has no potential conflicts of interest concerning drugs, pruducts, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
25. 7. 2012

Accepted:
30. 7. 2012

Zdroje

1. Llovet JM, Ricci S, Mazzaferro V et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–390.

2. Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008; 26 (Suppl): Abstract 4518.

3. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10(1): 25–34.

4. Wörns MA, Weinmann A, Pfingst K et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol 2009; 43(5): 489–495.

5. Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 2009; 14(1): 70–76.

6. Pinter M, Hucke F, Graziadei I et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012; 263(2): 590–599.